alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H. Con. Res. 120 Enrolled Bill (ENR)]

        H.Con.Res.120
                                         Agreed to July 31, 2024        

                     One Hundred Eighteenth Congress

                                 of the

                        United States of America

                          AT THE SECOND SESSION

         Begun and held at the City of Washington on Wednesday,
         the third day of January, two thousand and twenty-four

                          Concurrent Resolution

    Resolved by the House of Representatives (the Senate concurring),

SECTION 1. USE OF EMANCIPATION HALL FOR A CEREMONY AS PART OF THE 
              UNVEILING OF THE STATUE OF JOHNNY CASH.

    (a) Authorization.--Emancipation Hall in the Capitol Visitor Center 
is authorized to be used on September 24, 2024, for a ceremony as part 
of the unveiling of the statue of Johnny Cash, provided by the State of 
Arkansas.
    (b) Preparations.--Physical preparations for the ceremony described 
in subsection (a) shall be carried out in accordance with such 
conditions as the Architect of the Capitol may prescribe.
Attest:

                                 Clerk of the House of Representatives.

Attest:

                                               Secretary of the Senate.
```
<PAGE>
                                                                    EXHIBIT 10.8


                                 AMENDMENT NO. 1
                   TO THE EMPLOYMENT AND COMPENSATION AGREEMENT
                 BETWEEN CHOICEPOINT INC. AND DOUGLAS C. CURLING
                              DATED APRIL 25, 2002

Pursuant to the action of the Management Compensation and Benefits Committee
taken on February 4, 2003, the Employment and Compensation Agreement between
ChoicePoint, Inc. and Douglas C. Curling dated April 25, 2002, is hereby amended
as of February 4, 2003, effective for all years ending on or after 12/31/02, to
delete on Exhibit B, Compensation, Benefits and Severance the amount of $25,000
from the column Amount and next to the Benefit - Financial Planning/Tax
Preparation and replace it with the amount of $50,000.

                                Employer
                                CHOICEPOINT, INC.

                                By: /s/  Ken Langone
                                    -----------------------------------------

                                Name: Ken Langone

                                Title:Chairman: Management Compensation and
                                Benefits Committee

                                EXECUTIVE:

                                    /s/ Douglas C Curling
                                    -----------------------------------------
<TABLE> <S> <C>


        <S> <C>

<PAGE>

<ARTICLE>5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE AUDITED FINANCIAL STATEMENTS CONTAINED IN THE
REGISTRANT'S FORM 10-KSB AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>1

<S>                                                      <C>
<PERIOD-TYPE>                                                YEAR
<FISCAL-YEAR-END>                                            DEC-31-1999
<PERIOD-START>                                               JAN-01-1999
<PERIOD-END>                                                 DEC-31-1999
<CASH>                                                       2,336
<SECURITIES>                                                 0
<RECEIVABLES>                                                0
<ALLOWANCES>                                                 0
<INVENTORY>                                                  0
<CURRENT-ASSETS>                                             2,336
<PP&E>                                                       633
<DEPRECIATION>                                               422
<TOTAL-ASSETS>                                               1,113,549
<CURRENT-LIABILITIES>                                        262,477
<BONDS>                                                      0
<PREFERRED-MANDATORY>                                        0
<PREFERRED>                                                  0
<COMMON>                                                     12,016
<OTHER-SE>                                                   851,072
<TOTAL-LIABILITY-AND-EQUITY>                                 1,113,549
<SALES>                                                      0
<TOTAL-REVENUES>                                             0
<CGS>                                                        0
<TOTAL-COSTS>                                                0
<OTHER-EXPENSES>                                             167,196
<LOSS-PROVISION>                                             0
<INTEREST-EXPENSE>                                           44,229
<INCOME-PRETAX>                                             (211,425)
<INCOME-TAX>                                                 0
<INCOME-CONTINUING>                                         (211,425)
<DISCONTINUED>                                               0
<EXTRAORDINARY>                                              0
<CHANGES>                                                    0
<NET-INCOME>                                                (211,425)
<EPS-BASIC>                                               (.02)
<EPS-DILUTED>                                               (.02)



</TABLE>
[Federal Register Volume 60, Number 83 (Monday, May 1, 1995)]
[Notices]
[Page 21224]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10581]



=======================================================================
-----------------------------------------------------------------------

NATIONAL SCIENCE FOUNDATION


Advisory Panel for Cognitive, Psychological & Language Sciences; 
Meeting

    In accordance with the Federal Advisory Committee Act (Pub. L. 92-
463, as amended), the National Science Foundation (NSF) announces the 
following meeting for the Advisory Panel for Cognitive, Psychological & 
Language Sciences (#1758).

    Name: Advisory Panel for Cognitive, Psychological & Language 
Science (#1758).
    Date and Time: May 19, 1995, 9 a.m.-5 p.m.
    Place: National Science Foundation, 4201 Wilson Boulevard, Room 
970, Arlington, VA 22230.
    Contact Person: Paul G. Chapin, Program Director for 
Linguistics, National Science Foundation, 4201 Wilson Boulevard, 
Arlington, VA 22230. Telephone: (703) 306-1731.
    Agenda: To review and evaluate the outcome of NSF-funded 
projects in Linguistics.
    Type of Meeting: Closed.
    Purpose of Meeting: To provide advice and recommendations 
concerning the results and impacts of research projects funded by 
the NSF.
    Purpose for Closing: The actions being reviewed include 
information of a proprietary or confidential nature, including 
technical information, financial data, such as salaries; and 
personal information concerning individuals associated with the 
actions. These matters are exempt under 5 U.S.C. 552b(c) (4) and (6) 
of the Government in the Sunshine Act.

    Dated: April 26, 1995.
M. Rebecca Winkler,
Committee Management Officer.
[FR Doc. 95-10581 Filed 4-28-95; 8:45 am]
BILLING CODE 7555-01-M
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

NOT FOR CITATION

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

SAN JOSE DIVISION

UNITED STATES ex rel. DONNA M.

McLEAN and THE STATE OF CALIFORNIA 

ex rel DONNA M. McLEAN,

Plaintiffs,

 v.

THE COUNTY OF SANTA CLARA, THE

DEPARTMENT OF CHILDREN AND

FAMILY SERVICES OF SANTA CLARA

COUNTY, KENNETH BORELLI,

LAWRENCE GALLEGOS, EPIFANIO (“J.R.”)

REYNA, TANYA BEYERS, DR. DEE

SCHAEFFER, DR. TOMMIJEAN THOMAS,

DR. RICHARD PERILLO and DOES 1-100,

Defendants. /

COUNTY OF SANTA CLARA,

Counter-claimant,

 v.

DONNA M. McLEAN and DOES 1-100,

Counter-defendants. /

No. C05-01962 HRL

ORDER GRANTING DEFENDANT

THOMAS’ REQUEST FOR

TELEPHONIC APPEARANCE

[Docket No. 84]

Counsel for defendant Dr. Tommijean Thomas requests leave to appear by telephone at

the motion hearing and status conference set for May 15, 2007, 10:00 a.m. Upon consideration

*E-FILED: 5/3/2007*

Case 5:05-cv-01962-HRL Document 85 Filed 05/03/07 Page 1 of 3
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

2

of the papers presented, and good cause appearing, the request for telephonic appearance is

GRANTED.

Dated: ________________________________

HOWARD R. LLOYD

UNITED STATES MAGISTRATE JUDGE

May 3, 2007

Case 5:05-cv-01962-HRL Document 85 Filed 05/03/07 Page 2 of 3
United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

3

5:05-cv-1962 Notice will be electronically mailed to:

Virginia Stewart Alspaugh Virginia_Alspaugh@cmwlaw.net, Linda_Knobbe@cmwlaw.net;

TheAlspaughs@cox.net 

Orley Brandt Caudill , Jr brandt_caudill@cmwlaw.net, christopher_zopatti@cmwlaw.net 

Melissa R. Kiniyalocts melissa.kiniyalocts@cco.co.scl.ca.us 

Douglas A Linde dal@lindelaw.net, ela@lindelaw.net 

Sara McLean sara.mclean@usdoj.gov 

Sara Winslow sara.winslow@usdoj.gov, kathy.terry@usdoj.gov; claire.muller@usdoj.gov 

Counsel are responsible for distributing copies of this document to co-counsel who have

not registered for e-filing under the court’s CM/ECF program.

5:05-cv-1962 Notice will be delivered by mail to:

Donna McLean

1316 Arroyo Seco Drive

Campbell, CA 95008

Julia Clayton

Deputy Attorney General

California Attorney General’s Office

455 Golden Gate Avenue, Suite 11000

San Francisco, CA 94102-7004

Case 5:05-cv-01962-HRL Document 85 Filed 05/03/07 Page 3 of 3
```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 750 Agreed to Senate (ATS)]

<DOC>

117th CONGRESS
  2d Session
S. RES. 750

   Celebrating the United States-Republic of Korea alliance and the 
   dedication of the Wall of Remembrance at the Korean War Veterans 
                       Memorial on July 27, 2022.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             August 6, 2022

 Mr. Sullivan (for himself and Ms. Duckworth) submitted the following 
             resolution; which was considered and agreed to

_______________________________________________________________________

                               RESOLUTION

 
   Celebrating the United States-Republic of Korea alliance and the 
   dedication of the Wall of Remembrance at the Korean War Veterans 
                       Memorial on July 27, 2022.

Whereas, formed with the signing of the Mutual Defense Treaty Between the United 
        States and the Republic of Korea, done at Washington October 1, 1953, 
        the United States-Republic of Korea alliance is the linchpin of peace, 
        security, and prosperity for Northeast Asia, a free and open Indo-
        Pacific region, and across the world;
Whereas United States-Republic of Korea military and defense ties are 
        unwavering, and our ever-increasing economic, technological, diplomatic, 
        people-to-people, and values-based bonds are strong and enduring;
Whereas the United States commitment to the defense of the Republic of Korea 
        remains ironclad, and the alliance continues to work toward our shared 
        goals of securing peace, stability, and prosperity on the Korean 
        Peninsula and throughout the Indo-Pacific;
Whereas the Wall of Remembrance at the Korean War Veterans Memorial was 
        dedicated on July 27, 2022, with the names of more than 36,600 members 
        of the United States Armed Forces who lost their lives in the Korea 
        conflict, along with more than 7,100 Korean Augmentation to the United 
        States Army personnel who died serving alongside them;
Whereas the names of the United States and Republic of Korean fallen are 
        integrated to reflect the shared burden they bore to defend the Republic 
        of Korea; and
Whereas the Republic of Korea and its citizens funded nearly the entire 
        $22,000,000 cost of building the Wall of Remembrance: Now, therefore, be 
        it
    Resolved, That the Senate deeply appreciates and sincerely thanks 
the Government and people of the Republic of Korea for their generosity 
in funding the Wall of Remembrance, reflecting the shared sacrifice and 
common values of the United States-Republic of Korea alliance.
                                 <all>
```
Lonnie Irvan SLOAN, Appellant, v. STATE of Florida, Appellee.

Case No. 5D18-2823

District Court of Appeal of Florida, Fifth District.

Decision filed June 25, 2019

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
FDA EXTERNAL FACT SHEET 

Office of Regulatory Affairs (ORA), 

Office of Regulatory Science (ORS) 

ORS operates ORA’s 15 ISO:IEC 17205 accredited 

laboratories, located strategically across the 

United States and its territories. ORS supports the 

Agency’s mission to protect public health by 

providing a strong scientific basis for decision 

making and problem solving through the analysis

of samples, by conducting applied research and 

method development, by supporting compliance 

and surveillance programs, by ensuring strong 

laboratory operations, and by ensuring safe 

working conditions for all ORA employees. The 

laboratories are aligned into two commoditydriven programs – Medical Products and Specialty 

Laboratory Operations, and Human and 

Animal Food Laboratory Operations – to ensure

adequate service to all programs across the country. 

There are approximately 930 scientists and support staff within ORS. These individuals support the scientific 

mission of the Agency with expertise in chemical, microbiological, engineering, radiochemical, and forensic methods 

of analysis. As a direct result of this work, the FDA is able to identify products found to be in violation of the Food, 

Drug and Cosmetic Act and take action to prevent importation or initiate domestic compliance action. 

ORS is led by a director who, along with a senior management team, oversees day-to-day operations and 

provides strategic scientific leadership, coordination, and expertise to ORA laboratories and leaders. The director 

reports to ORA’s Deputy Associate Commissioner for Regulatory Affairs (DACRA).

ORS includes four offices: the Office of Safety; the Office of Research Coordination and Evaluation (which includes 

laboratory quality system oversight and support); the Office of Human and Animal Food Laboratory Operations; and 

the Office of Medical Products and Specialty Lab Operations (which includes the Forensic Chemistry Center, 

the Tobacco Products Laboratory, and the Winchester Engineering Analytical Center).

For more information, visit: About the Office of Regulatory Affairs or contact: engageORA@fda.hhs.gov

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring 

the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human 

use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, 

cosmetics, dietary supplements, and products that give off electronic radiation, and for regulating tobacco products.
## In the

Court of Appeals

Second Appellate District of Texas

at Fort Worth

___________________________

No. 02

- 22

- 00075

- CV

___________________________

Original Proceeding

County Court at Law No. 2 of Denton County, Texas

Trial Court No. CV

- 2020

- 03039

Before Bassel, Kerr, and Walker, JJ.

Per Curiam Memorandum Opinion 

### I N RE 

### T EXAS 

### A IR 

### C LASSICS



### , I NC



### . , Relator2 MEMORANDUM OPINION

The court has considered relator’s “ 1 st Am e n d ed P etition for Writ of

Mandamus ” and “ Motion for Emergency Temporary Relief ” and is of the opinion

that relief should be denied. Accordingly, relator’s “ 1 st Am e n d ed P etition for Writ of

Mandamus ” and “ Motion for Emergency Temporary Relief ” are denied.

Per Curiam

Delivered : March 8, 2022
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

SAN JOSE DIVISION

NGOC LAM CHE,

Plaintiff,

v.

SAN TE PROPERTIES, LLC,

Defendant.

Case No. 5:17-cv-00106-HRL 

ORDER TO SHOW CAUSE RE 

SETTLEMENT

Re: Dkt. No. 17

The court having been informed that this case has settled, all previously scheduled 

deadlines and appearances are vacated.

On or before September 26, 2017, the parties shall file a stipulated dismissal pursuant to 

Fed. R. Civ. P. 41(a). If a dismissal is not filed by the specified date, then the parties shall appear

in Courtroom 2, 5th Floor of the United States District Court, 280 South First Street, San Jose, 

California on October 3, 2017, 10:00 a.m. and show cause, if any, why the case should not be 

dismissed pursuant to Fed. R. Civ. P. 41(a). Additionally, the parties shall file a statement in 

response to this Order to Show Cause no later than September 27, 2017 advising as to (1) the 

status of the activities of the parties in finalizing settlement; and (2) how much additional time, if 

any, is requested to finalize the settlement and file the dismissal. If a dismissal is filed as ordered, 

the Order to Show Cause hearing will be automatically vacated and the parties need not file a 
2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

statement in response to this Order.

SO ORDERED.

Dated: July 31, 2017

Howard R. Lloyd

United States Magistrate Judge
3

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

5:17-cv-00106-HRL Notice has been electronically mailed to:

Michael W. Thomas mthomas@thomas-lawyers.com

Pamela Tsao pamela.tsao@ascensionlawgroup.com
Exhibit 10.9


 


FIRST AMENDMENT TO

AMENDED AND RESTATED EMPLOYMENT AGREEMENT


 










 


THIS FIRST AMENDMENT TO AMENDED AND RESTATED
EMPLOYMENT AGREEMENT (this “Amendment Agreement”) dated January     ,
2009, is between Tuesday Morning Corporation, a Delaware corporation (the “Company”),
and Kathleen Mason (“Executive”).


 


WHEREAS, the Company and Executive entered into an
amended and restated employment agreement dated September 29, 2008 (the “Amended
and Restated Employment Agreement”); and


 


WHEREAS, the Company and Executive wish to amend the
Amended and Restated Employment Agreement; now therefore:


 


In consideration of the mutual covenants contained
herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:


 


1.             Paragraph 3(d) of the Amended and Restated
Employment Agreement is hereby amended to read as follows in its entirety:


 


“(d) In connection with her employment under this Agreement,
Executive shall be granted by the Company under the 2008 Plan a restricted
stock award of 364,078 shares of Common Stock as promptly as practicable.  The restricted stock award shall be subject
to substantial risk of forfeiture restrictions one-third of which shall lapse
on each of November 14, 2009, November 14, 2010, and November 14,
2011.  In addition, during the Employment
Period, the Company shall pay Executive an amount equal to $500,000 per year on
each of November 14, 2009, November 14, 2010 and November 14,
2011.”


 


2.             Capitalized terms used in this Amendment Agreement and
not otherwise defined shall have the meanings ascribed to them in the Amended
and Restated Employment Agreement.


 


3.             This Amendment Agreement may be executed in separate
counterparts, each of which is deemed to be an original and all of which taken
together constitute one and the same agreement.


 


4.             Any references to the Amended and Restated Employment
Agreement in any other document shall be deemed to mean the Amended and
Restated Employment Agreement, as amended by this Amendment Agreement.


 


5.             The Amended and Restated Employment Agreement, as
amended by this Amendment Agreement, shall remain in full force and effect.


 


1

















 


IN WITNESS WHEREOF, the parties hereto have duly
executed this Amendment Agreement on the date first written above.


 


 


	
   

  	
  TUESDAY MORNING CORPORATION

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
    /s/ Stephanie Bowman

  
	
   

  	
  Name:

  	
  Stephanie Bowman

  
	
   

  	
  Title:

  	
  Executive Vice President and Chief

  Financial Officer

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ Kathleen Mason

  
	
   

  	
   

  	
  Kathleen Mason

  
					



 


2
Fourth Court of Appeals

San Antonio, Texas

January 28, 2022

No. 04-21-00584-CV

TITLE SOURCE, INC., Reporters Committee for Freedom of the Press, and Houston Forward 

Times,

Appellants

v.

HOUSECANARY, INC., d/k/a Canary Analytics, Inc.,

Appellee

From the 73rd Judicial District Court, Bexar County, Texas

Trial Court No. 2016CI06300

Honorable David A. Canales, Judge Presiding

O R D E R

On January 26, 2022, appellant filed (1) a Resident Attorney’s Motion in Support of 

Motion for Pro Hac Vice Admission of Helgi C. Walker and (2) an Unopposed Motion for Pro 

Hac Vice Admission of Helgi C. Walker, each requesting this court allow Helgi C. Walker to 

appear pro hac vice to serve as appellate co-counsel for appellant. The motions are GRANTED.

_________________________________

Irene Rios, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 28th day of January, 2022.

___________________________________

MICHAEL A. CRUZ, Clerk of Court
Datos acerca de los medicamentos genéricos 

Los medicamentos genéricos tienen la misma alta calidad que sus versiones 

de marca. 

Los medicamentos genéricos pasan por un riguroso proceso de 

examinación para recibir la aprobación de la Administración de 

Alimentos y Medicamentos (Food and Drug Administration, FDA 

por sus siglas en inglés). La FDA se asegura de que los medicamentos 

genéricos proporcionen los mismos beneficios clínicos y que sean tan 

seguros y efectivos como los medicamentos de marca originales. 

Los medicamentos genéricos y de marca son iguales 

en los siguientes aspectos: 

✓Ingredientes activos ✓Eficacia ✓Calidad 

✓Seguridad ✓Potencia ✓Beneficios

Pero pueden verse diferentes. 

Las diferencias permisibles en tamaño, forma y color no afectan la manera en 

que funcionan los medicamentos. Los medicamentos genéricos pueden tener 

una apariencia distinta a los medicamentos de marca equivalentes, pero son 

igual de seguros y efectivos. 

Y pueden costar mucho menos. 

Los medicamentos genéricos tienden a costar menos que sus equivalentes de marca porque no tienen 

que repetir los estudios en animales y estudios clínicos (en humanos) que fueron exigidos a los 

medicamentos de marca para demostrar su seguridad y eficacia.

Cuando múltiples empresas de genéricos comercializan el mismo producto, la competencia en el 

mercado generalmente resulta en precios alrededor de un 85 % más bajo que los productos de marca. 

Aprenda más sobre medicamentos genéricos. Visite www.fda.gov/genericos. 

www.fda.gov